{
    "Clinical Trial ID": "NCT00405938",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Bevacizumab/Anastrozole",
        "  Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.",
        "INTERVENTION 2: ",
        "  Bevacizumab/Fulvestrant",
        "  Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg intramuscular on Day 1 of Cycle 1, followed by 250 mg intramuscular of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg intramuscular of fulvestrant). Treatment will be given in 4-week cycles."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Postmenopausal breast cancer (adenocarcinoma) estrogen (ER)and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis",
        "  Female patients 18 years or older",
        "  Documentation of ER+ and/or PR+",
        "  No prior chemotherapy or hormone therapy for metastatic breast cancer or inoperable breast cancer that is locally recurrent or locally advanced",
        "  Measurable or evaluable disease",
        "  Radiation therapy to painful bone lesions or impending fractures is allowed as long as there is measurable or evaluable disease outside the radiated area.",
        "  Must have adequate bone marrow, renal and liver function",
        "  Patients receiving prior treatment with an anthracycline based chemotherapy must have a normal left ventricle ejection fraction",
        "Exclusion Criteria:",
        "  No metastatic disease to the Central Nervous System",
        "  No history of myocardial infarction (MI), stroke or transient ischemic attacks in the last 6 months",
        "  No symptoms of peripheral vascular disease",
        "  No history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months",
        "  No known hypersensitivity to phosphate, trehalose or polysorbate",
        "  No serious non-healing wound, ulcer or bone fracture",
        "  No uncontrolled high blood pressure or history of hypertensive crisis",
        "  No New York Hear Association class II congestive heart failure",
        "  No extensive cancer involvement of the liver or lungs",
        "  No history of significant psychiatric disorders",
        "  No significant vascular disease",
        "  There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease",
        "  Progression Free Survival (PFS) is defined as the interval, in months, from the date of first treatment to the date of disease progression or death, whichever occurred first.",
        "  Time frame: 18 months",
        "Results 1: ",
        "  Arm/Group Title: Bevacizumab/Anastrozole",
        "  Arm/Group Description: Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.",
        "  Overall Number of Participants Analyzed: 38",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  21  [1]    (14 to NA)",
        "Results 2: ",
        "  Arm/Group Title: Bevacizumab/Fulvestrant",
        "  Arm/Group Description: Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg intramuscular on Day 1 of Cycle 1, followed by 250 mg intramuscular of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg intramuscular of fulvestrant). Treatment will be given in 4-week cycles.",
        "  Overall Number of Participants Analyzed: 41",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  9        (5 to 13)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/38 (26.32%)",
        "  cTnI  [1]0/38 (0.00%)",
        "  Superventricular Arrhythmia - Sinus Bradycardia 1/38 (2.63%)",
        "  Pain - Cardiac 0/38 (0.00%)",
        "  Cardiac Ischemia/Infarction 0/38 (0.00%)",
        "  Restrictive Cardiomyopathy 1/38 (2.63%)",
        "  Dehydration 0/38 (0.00%)",
        "  Diarrhea 1/38 (2.63%)",
        "  Vomiting 1/38 (2.63%)",
        "  Nausea 1/38 (2.63%)",
        "  Death 0/38 (0.00%)",
        "  Weakness 1/38 (2.63%)",
        "Adverse Events 2:",
        "  Total: 12/41 (29.27%)",
        "  cTnI  [1]1/41 (2.44%)",
        "  Superventricular Arrhythmia - Sinus Bradycardia 0/41 (0.00%)",
        "  Pain - Cardiac 1/41 (2.44%)",
        "  Cardiac Ischemia/Infarction 1/41 (2.44%)",
        "  Restrictive Cardiomyopathy 0/41 (0.00%)",
        "  Dehydration 1/41 (2.44%)",
        "  Diarrhea 0/41 (0.00%)",
        "  Vomiting 0/41 (0.00%)",
        "  Nausea 0/41 (0.00%)",
        "  Death 1/41 (2.44%)",
        "  Weakness 0/41 (0.00%)"
    ]
}